000303442 001__ 303442
000303442 005__ 20250812114503.0
000303442 0247_ $$2doi$$a10.1002/ijc.70070
000303442 0247_ $$2pmid$$apmid:40749126
000303442 0247_ $$2ISSN$$a0020-7136
000303442 0247_ $$2ISSN$$a1097-0215
000303442 037__ $$aDKFZ-2025-01655
000303442 041__ $$aEnglish
000303442 082__ $$a610
000303442 1001_ $$00000-0002-7684-3122$$aRashid, Muhammad Usman$$b0
000303442 245__ $$aGenetic landscape of Pakistani familial breast cancer patients using multigene panel testing.
000303442 260__ $$aBognor Regis$$bWiley-Liss$$c2025
000303442 3367_ $$2DRIVER$$aarticle
000303442 3367_ $$2DataCite$$aOutput Types/Journal article
000303442 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1754913072_16539
000303442 3367_ $$2BibTeX$$aARTICLE
000303442 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000303442 3367_ $$00$$2EndNote$$aJournal Article
000303442 500__ $$a#LA:B072# / epub
000303442 520__ $$aPathogenic/likely pathogenic (P/LP) variants in high-, moderate-, and low-penetrance genes account for approximately half of all familial breast cancer (BC) cases. In Pakistan, data on P/LP variants beyond BRCA1/2 remain limited. This study investigated the frequency and distribution of P/LP variants in Pakistani familial BC patients using a 14-gene hereditary breast and ovarian cancer (HBOC) core panel. A total of 160 familial BC patients previously tested negative for protein-truncating variants in BRCA1, BRCA2, CHEK2, PALB2, RAD51C, RAD51D, and TP53 using conventional methods were included. Next-generation sequencing (NGS) was performed using the Illumina MiSeq platform, and all identified P/LP variants were validated by Sanger sequencing. Twenty-four unique P/LP variants were identified across seven genes: BRCA1 (n = 10), BRCA2 (n = 6), TP53 (n = 3), CHEK2 (n = 2), PALB2, ATM, and RAD51C (n = 1 each). Two recurrent BRCA1 variants, p.Gln169Ter and p.Val757Phefs*8, were identified in three patients each. NGS-detected P/LP variants were identified in 18.1% (29/160) of patients. When combined with previous germline testing in the same cohort, the overall detection rate increased to 50.2% (132/263): BRCA1 (101/263; 38.4%), BRCA2 (22/263; 8.4%), TP53 (3/263; 1.1%), CHEK2 (2/263; 0.8%), PALB2 (2/263; 0.8%), ATM (1/263; 0.4%) and RAD51C (1/263; 0.4%). Among these, BRCA1/2 variants accounted for 93.2% (123/132) of all P/LP variants. Our findings demonstrate that P/LP variants are concentrated in a limited number of genes, with BRCA1/2 as the predominant contributors. We propose a cost-effective, first-tier genetic testing panel comprising seven genes (ATM, BRCA1, BRCA2, CHEK2, RAD51C, PALB2, and TP53) for familial BC risk assessment in Pakistan.
000303442 536__ $$0G:(DE-HGF)POF4-312$$a312 - Funktionelle und strukturelle Genomforschung (POF4-312)$$cPOF4-312$$fPOF IV$$x0
000303442 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000303442 650_7 $$2Other$$aPakistan
000303442 650_7 $$2Other$$afamilial breast cancer
000303442 650_7 $$2Other$$anext‐generation sequencing
000303442 650_7 $$2Other$$apathogenic variants
000303442 7001_ $$aMuhammad, Noor$$b1
000303442 7001_ $$aArif, Shumaila$$b2
000303442 7001_ $$aNaeemi, Humaira$$b3
000303442 7001_ $$0P:(DE-He78)537e07b3e57b16c7b214fc2242e4326b$$aHamann, Ute$$b4$$eLast author
000303442 773__ $$0PERI:(DE-600)1474822-8$$a10.1002/ijc.70070$$gp. ijc.70070$$pnn$$tInternational journal of cancer$$vnn$$x0020-7136$$y2025
000303442 909CO $$ooai:inrepo02.dkfz.de:303442$$pVDB
000303442 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)537e07b3e57b16c7b214fc2242e4326b$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000303442 9131_ $$0G:(DE-HGF)POF4-312$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunktionelle und strukturelle Genomforschung$$x0
000303442 9141_ $$y2025
000303442 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2024-12-17$$wger
000303442 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2024-12-17$$wger
000303442 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-17
000303442 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-17
000303442 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-17
000303442 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2024-12-17
000303442 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-17
000303442 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2024-12-17
000303442 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2024-12-17
000303442 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-17
000303442 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-17
000303442 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bINT J CANCER : 2022$$d2024-12-17
000303442 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bINT J CANCER : 2022$$d2024-12-17
000303442 9202_ $$0I:(DE-He78)B072-20160331$$kB072$$lMolekulargenetik des Mammakarzinoms$$x0
000303442 9201_ $$0I:(DE-He78)B072-20160331$$kB072$$lMolekulargenetik des Mammakarzinoms$$x0
000303442 980__ $$ajournal
000303442 980__ $$aVDB
000303442 980__ $$aI:(DE-He78)B072-20160331
000303442 980__ $$aUNRESTRICTED